Eli Lilly to acquire Calytrix Bio for up to $1.5B
Eli Lilly has agreed to acquire Calytrix Bio, a privately held, JPMorgan-backed company developing therapies for rare blood cancers, for up to $1.5 billion, per the Wall Street Journal. The deal adds oncology assets to Lilly's pipeline as it continues to diversify beyond metabolic drugs. The price tag of up to $1.5B signals Lilly's willingness to pay up for early-stage oncology science.
Source:
Wsj: https://www.wsj.com/business/deals/eli-lilly-to-buy-calytrix-bio-for-up-to-1-5-billion-591745e4
Not financial advice. For informational and educational purposes only.